GSK BENEFITS FROM RSV VACCINE

GSK raised its guidance for the second time this year as demand surges for its breakthrough vaccine to prevent a common respiratory virus in adults. The UK pharmaceutical company now expects sales to increase by as much as 13 percent and adjusted earnings per share to rise as much as 20 percent this fiscal year. The pickup in performance has been driven in part by the successful launch of Arexvy, the new RSV vaccine for older adults.